Aurinia Pharmaceuticals Inc. (AUPH) research
Aurinia Pharmaceuticals Inc.- Sector
- Biotechnology
- Last price
- $15.83
- As of
Aurinia Pharmaceuticals Inc. (AUPH): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-19.
As of . Source: SEC EDGAR filings for AUPH. Method and limitations.
Share the AUPH intelligence card
See the full AUPH dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AUPH on one page. Preview it with sample data, then open it live with a free account.
Preview the AUPH dossierActive signals for AUPH
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +109% to AUPH (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +121% to AUPH (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 14.4%, EPS $0.28 vs $0.2448 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 84% of AUPH (2026Q1)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +75% to AUPH (2026Q1)
FREE, NO ACCOUNT
Every signal on AUPH, as it fires
You are seeing 5 of 11 signals recorded on AUPH since 2026-05-31.
The five above landed across 3 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AUPH (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 05156V102 · 2026Q2 | $58.8M | 0.04% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 05156V102 · 2026Q2 | $26.3M | 0.04% | , |
| D. E. Shaw & Co., Inc.CUSIP 05156V102 · 2026Q2 | $23.9M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 05156V102 · 2026Q2 | $4.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 05156V102 · 2026Q2 | $4.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AUPH
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AUPH against its peers
AUPH's operating margin of 37.1% ranks in the 84th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | AUPH | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 283M USD | 106M USD | 78 | 15 |
| Operating margin | 37.1% | -141.4% | 84 | 15 |
| Net margin | 101.5% | -108.2% | 97 | 16 |
| Return on equity | 49.4% | -34.6% | 98 | 21 |
| P / E | 7.6x | n/a | n/a | 3 |
Peers (23): PHVS, MLYS, ADMA, BCRX, VRDN, VERA, VCEL, PVLA, URGN, SLS, SRPT, AGIO, RXRX, NRIX, IMNM, BHVN, LKFT, ZYME, IRON, BEAM, XNCR, MESO, CLDX. Left out: ADRX (no annual filing), GENB (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (AUPH: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more AUPH signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AUPHand get the insider, 13F, options, and confluence read in one view.